[go: up one dir, main page]

MX2019005751A - Tratamiento de enfermedades e infecciones de las vias respiratorias con composiciones de acido ascorbico. - Google Patents

Tratamiento de enfermedades e infecciones de las vias respiratorias con composiciones de acido ascorbico.

Info

Publication number
MX2019005751A
MX2019005751A MX2019005751A MX2019005751A MX2019005751A MX 2019005751 A MX2019005751 A MX 2019005751A MX 2019005751 A MX2019005751 A MX 2019005751A MX 2019005751 A MX2019005751 A MX 2019005751A MX 2019005751 A MX2019005751 A MX 2019005751A
Authority
MX
Mexico
Prior art keywords
infections
diseases
treatment
ascorbic acid
respiratory tract
Prior art date
Application number
MX2019005751A
Other languages
English (en)
Inventor
Copeland Dan
Durham Carolyn
e richardson Thomas
Original Assignee
Renovion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovion Inc filed Critical Renovion Inc
Publication of MX2019005751A publication Critical patent/MX2019005751A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/18—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof
    • A01N37/30—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof containing the groups —CO—N< and, both being directly attached by their carbon atoms to the same carbon skeleton, e.g. H2N—NH—CO—C6H4—COOCH3; Thio-analogues thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
    • A01N37/46—N-acyl derivatives
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Molecular Biology (AREA)

Abstract

La solicitud se relaciona con un método para inhibir o reducir el crecimiento de bacterias de aislado clínico que comprende poner en contacto el aislado clínico con una composición que comprende glutatión, un derivado de glutatión, un conjugado de glutatión, una sal farmacéuticamente aceptable del mismo o cualquier combinación de los mismos.
MX2019005751A 2016-11-17 2017-11-17 Tratamiento de enfermedades e infecciones de las vias respiratorias con composiciones de acido ascorbico. MX2019005751A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423702P 2016-11-17 2016-11-17
US201662423721P 2016-11-17 2016-11-17
PCT/US2017/062412 WO2018094278A1 (en) 2016-11-17 2017-11-17 Treatment of respiratory tract diseases and infections with glutathione compositions

Publications (1)

Publication Number Publication Date
MX2019005751A true MX2019005751A (es) 2019-11-12

Family

ID=62146825

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019005751A MX2019005751A (es) 2016-11-17 2017-11-17 Tratamiento de enfermedades e infecciones de las vias respiratorias con composiciones de acido ascorbico.
MX2024008221A MX2024008221A (es) 2016-11-17 2019-05-16 Composicion que comprende glutation para usarse en inhibir o reducir el crecimiento de bacterias de un aislado clinico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024008221A MX2024008221A (es) 2016-11-17 2019-05-16 Composicion que comprende glutation para usarse en inhibir o reducir el crecimiento de bacterias de un aislado clinico.

Country Status (11)

Country Link
US (2) US11602555B2 (es)
EP (1) EP3541401A4 (es)
KR (3) KR20260004557A (es)
CN (1) CN110198728A (es)
AU (1) AU2017362500B2 (es)
CA (1) CA3043892A1 (es)
IL (1) IL266619A (es)
MX (2) MX2019005751A (es)
NZ (1) NZ753749A (es)
WO (1) WO2018094278A1 (es)
ZA (1) ZA201903893B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ753749A (en) * 2016-11-17 2025-10-31 Renovion Inc Treatment of respiratory tract diseases and infections with glutathione compositions
FI3710036T3 (fi) * 2017-11-17 2024-12-27 Renovion Inc Stabiileja askorbiinihappokoostumuksia ja menetelmiä niiden käyttämiseksi
WO2019157295A1 (en) * 2018-02-09 2019-08-15 The Trustees Of Columbia University In The City Of New York Treating infections using inhibitor of cbb3-type oxidases
CN109224062A (zh) * 2018-09-30 2019-01-18 浙江肽明生物科技有限公司 一种新型多肽高效抗菌素及其制备方法
KR102464435B1 (ko) * 2020-09-22 2022-11-07 의료법인 성광의료재단 D-글루타티온을 포함하는 염증 질환의 예방 또는 치료용 조성물
CN118632703A (zh) * 2022-01-04 2024-09-10 莱诺翁股份有限公司 含有谷胱甘肽盐的水性溶液

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2606903A (en) 1944-03-29 1952-08-12 Physiological Chemicals Compan Ascorbic acid addition compound of sulfathiazole
DE2845484A1 (de) 1978-10-19 1980-04-30 Groening Ruediger Verfahren zur erhoehung der biologischen verfuegbarkeit von arzneistoffen
US4968716A (en) 1987-04-10 1990-11-06 Oxycal Laboratories, Inc. Compositions and methods for administering therapeutically active compounds
US5070085A (en) 1987-04-10 1991-12-03 Oxycal Laboratories, Inc. Compositions and methods for administering therapeutically active compounds
US4861783A (en) 1988-04-26 1989-08-29 E. I. Du Pont De Nemours And Company 4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases
US5304724A (en) 1988-09-09 1994-04-19 Entravision, Inc. Tissue irrigating solution
US5238683A (en) 1989-11-24 1993-08-24 The United States Of America As Represented By The Department Of Health And Human Services Aerosol preparation of glutathione and a method for augmenting glutathione level in lungs
DE69214467T3 (de) 1991-01-10 2000-09-28 Transcend Therapeutics, Inc. Verwendung von L-2-oxo Thiazolidin-4-carboxylat zur Behandlung von Atemnotsyndrom
US6764693B1 (en) 1992-12-11 2004-07-20 Amaox, Ltd. Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
US5626883A (en) 1994-04-15 1997-05-06 Metagenics, Inc. Ascorbic acid compositions providing enhanced human immune system activity
NZ335401A (en) 1996-11-01 2000-12-22 Xoma Corp Therapeutic uses of BPI protein products in cystic fibrosis patients
US6350467B1 (en) 1996-12-31 2002-02-26 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
US6896899B2 (en) 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
US5906811A (en) 1997-06-27 1999-05-25 Thione International, Inc. Intra-oral antioxidant preparations
US5829449A (en) 1997-09-19 1998-11-03 Thione International, Inc. Smoking products containing antioxidants
US6415798B1 (en) 1997-09-19 2002-07-09 Thione International, Inc. Antioxidants to neutralize tobacco free radicals
US6470894B2 (en) 1997-09-19 2002-10-29 Thione International, Inc. Glutathione, green tea, grape seed extract to neutralize tobacco free radicals
US6228347B1 (en) 1997-12-01 2001-05-08 Thione International, Inc. Antioxidant gel for gingival conditions
EP1100517A1 (en) 1998-08-04 2001-05-23 John V. Kosbab Nutrient and therapeutic compositions for the treatment of cancer
US6312734B1 (en) 1998-11-23 2001-11-06 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
KR100390630B1 (ko) 1999-07-02 2003-07-07 이희발 항 산화제를 함유한 복막투석액
DE19935763B4 (de) 1999-07-27 2006-03-02 Jenning, Volkhard, Dr. Zusammensetzung eines Redoxsystems zur Stabilisierung von Retinoiden in Präparaten zur äußerlichen Anwendung
US7045152B2 (en) 1999-09-08 2006-05-16 Duke University Treating pulmonary disorders with gaseous agent causing repletion of GSNO
US20020037855A1 (en) 2000-05-05 2002-03-28 Fritz Stanislaus Stabilized medicament containing cysteinyl derivatives
AU2001222986A1 (en) 2000-05-19 2001-12-03 Progenics Pharmaceuticals, Inc. Dehydroascorbic acid formulations and uses thereof
US6601580B1 (en) 2000-06-28 2003-08-05 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
US6485950B1 (en) 2000-07-14 2002-11-26 Council Of Scientific And Industrial Research Isozyme of autoclavable superoxide dismutase (SOD), a process for the identification and extraction of the SOD in cosmetic, food and pharmaceutical compositions
AU2002211222B2 (en) 2000-10-16 2006-02-09 Duke University Therapeutic use of aerosolized S-nitrosoglutathione in cystic fibrosis
US20020165207A1 (en) 2001-05-02 2002-11-07 Richard Rosenbloom Compositions and methods for the treatment of diabetic neuropathy
EP1353676A4 (en) 2000-12-29 2006-05-31 Alteon Inc METHOD FOR THE TREATMENT OF FIBROUS OR OTHER INDICATIONS
CA2446064A1 (en) 2001-05-02 2002-11-07 Nitromed, Inc. Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
EP1474158B1 (en) 2001-12-18 2009-10-14 Brassica Foundation for Chemoprotection Research, Inc. Prevention and treatment of oxidative stress disorders by compounds which elevate intracellular levels of glutathione or phase ii detoxification enzymes
AUPS019802A0 (en) 2002-01-31 2002-02-21 Chemstop Pty Ltd Nutrient formulation
US20040229815A1 (en) 2003-01-03 2004-11-18 Nagasawa Herbert T. Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug
CN1901801B (zh) * 2003-12-04 2013-01-16 衣阿华大学研究基金会 镓抑制生物膜形成
US20050271726A1 (en) 2004-06-02 2005-12-08 Albert Crum Immune enhancing compositions and methods of use thereof
DE102004035113A1 (de) 2004-07-20 2006-02-16 Degussa Ag alpha-Liponsäure enthaltende Zusammensetzung bei cystischer Fibrose
PL1817006T3 (pl) 2004-11-07 2013-03-29 F Timothy Guilford Liposomalny preparat do doustnego podawania glutationu (zredukowanego)
US8349359B2 (en) * 2004-11-07 2013-01-08 Your Energy Systems, LLC Liposomal formulation for oral administration of glutathione (reduced)
MX2007005975A (es) 2004-11-17 2007-10-08 Yissum Res Dev Co Uso de conjugados de lipido en el tratamiento de enfermedades.
US8703198B2 (en) 2005-03-02 2014-04-22 Aquatrove Biosciences Water-based personal moisturizers and lubricants, in particular vaginal lubricants, and uses thereof
US7601487B2 (en) 2005-04-12 2009-10-13 Cleo Cosmetic And Pharmaceutical Co., Llc Composition using HMW dextran and method for in vitro preservation of corneal tissues
US20060258599A1 (en) 2005-04-27 2006-11-16 Melanie Childers Methods and composition for the treatment of cystic fibrosis and related illnesses
DK2351828T3 (en) * 2005-05-24 2018-01-22 Univ Nanyang Tech Methods and compositions for regulating biofilm development
WO2007024876A2 (en) 2005-08-24 2007-03-01 The Board Of Trustees Of Leland Stanford Junior University Methods for treating and monitoring inflammation and redox imbalance in cystic fibrosis
US9333260B2 (en) 2006-05-10 2016-05-10 Laclede, Inc. Compositions and methods for enzymatic treatment of lung disorders
US20080008694A1 (en) 2006-07-05 2008-01-10 Elgebaly Salwa A Methods to prevent and treat diseases
US20100310541A1 (en) 2007-05-25 2010-12-09 Ironwood Pharmaceuticals, Inc. Compositions and Methods for Reducing the Toxicity of Certain Toxins
WO2009001884A1 (ja) 2007-06-26 2008-12-31 Kyowa Hakko Bio Co., Ltd. 酸化型グルタチオン錠
JP2011026204A (ja) 2007-11-26 2011-02-10 Rei Furukawa タバコの煙を吸入することにより引き起こされる疾患の予防及び／又は治療用組成物
WO2009099132A1 (ja) 2008-02-05 2009-08-13 Kyowa Hakko Bio Co., Ltd. グルタチオンの保存安定性向上方法
US9289462B2 (en) 2008-09-17 2016-03-22 Terry Gage Method for medical treatment utilizing glutathione
FR2941374B1 (fr) 2009-01-28 2011-03-11 Alaxia Utilisation d'une association synergique d'ions hypothiocyanites et/ou hypohalites et de lactoferrine pour la preparation pour le traitement de la mucoviscidose
US20120093947A1 (en) 2009-02-27 2012-04-19 United States Department Of Veterans Affairs Method of treating reactive airway disease
GB0908174D0 (en) 2009-05-13 2009-06-24 Isis Innovation Steroid containing composition and uses thereof
WO2011009213A1 (en) * 2009-07-20 2011-01-27 Innovotech, Inc. Testing of biofilm for anti-microbial agent susceptibility
CN101987195B (zh) 2009-08-06 2012-07-18 重庆市力扬医药开发有限公司 经口腔粘膜吸收的还原型谷胱甘肽药物
IT1401504B1 (it) 2010-08-02 2013-07-26 Cattarini Mastelli Composizione comprendente glutatione reduttasi e glutatione ossidato
WO2012027603A2 (en) 2010-08-26 2012-03-01 Clarity Products, Limited Liability Company Therapeutic consumable compositions for reduction of facial flush effect incident to alcohol consumption in persons with deficient activity of the aldehyde dehydrogenase gene-aldh2
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
CN102100904B (zh) 2011-01-25 2013-04-24 成都卓阳生物科技有限公司 还原型谷胱甘肽经皮吸收制剂及其制备方法
US10328152B2 (en) 2011-06-16 2019-06-25 Nayan Patel Method for stabilization and delivery of therapeutic molecules
US20130084336A1 (en) * 2011-06-27 2013-04-04 Albert Einstein College Of Medicine Of Yeshiva University Enhanced nitric oxide delivery and uses thereof
CN102329370B (zh) 2011-09-22 2015-07-22 山东金城医药化工股份有限公司 还原型谷胱甘肽单钠盐的制备方法
CA3153463A1 (en) * 2012-10-29 2014-05-08 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders
WO2014126594A1 (en) * 2013-02-15 2014-08-21 Guilford Frederick Timothy Treatment of evolving bacterial resistance diseases including klebsiella pneumoniae with liposomally formulated glutathione
US20140234397A1 (en) * 2013-02-15 2014-08-21 Lou Ann Brown Treatment of klebsiella pneumoniae with liposomally formulated glutathione
ITPD20130052A1 (it) 2013-03-01 2014-09-02 Enologica Vason S P A Procedimento di vinificazione e prodotto per uso enologico atto ad essere utilizzato in detto procedimento di vinificazione
GB201306980D0 (en) * 2013-04-17 2013-05-29 Blueberry Therapeutics Ltd Methods
WO2016037166A1 (en) 2014-09-07 2016-03-10 Yu Zhang Novel anti-oxidant compositions and methods of delivery
WO2016067283A1 (en) 2014-10-30 2016-05-06 Rice Howard Virucidal compositions comprising tannins for nasal and pulmonary administration
WO2016088116A1 (en) 2014-12-05 2016-06-09 University Health Network Use of antioxidants as radio-protective agents
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione
AU2017298202A1 (en) 2016-07-16 2019-02-07 Lauranell Harrison Burch Methods for treating cystic fibrosis and other diseases affecting mucosal surfaces
NZ753749A (en) 2016-11-17 2025-10-31 Renovion Inc Treatment of respiratory tract diseases and infections with glutathione compositions
FI3710036T3 (fi) 2017-11-17 2024-12-27 Renovion Inc Stabiileja askorbiinihappokoostumuksia ja menetelmiä niiden käyttämiseksi
KR20210119376A (ko) 2018-10-23 2021-10-05 조지 에드워드 호아그 폐를 치료하기 위한 조성물 및 방법
BR112023002926A2 (pt) 2020-08-26 2023-04-25 Cila Therapeutic Inc Agentes terapêuticos inaláveis

Also Published As

Publication number Publication date
ZA201903893B (en) 2020-12-23
KR20190097022A (ko) 2019-08-20
EP3541401A4 (en) 2020-07-29
IL266619A (en) 2019-07-31
NZ753749A (en) 2025-10-31
US20190351005A1 (en) 2019-11-21
US20230165929A1 (en) 2023-06-01
AU2017362500A1 (en) 2019-06-13
US12427180B2 (en) 2025-09-30
EP3541401A1 (en) 2019-09-25
KR20230117644A (ko) 2023-08-08
AU2017362500B2 (en) 2024-09-26
US11602555B2 (en) 2023-03-14
KR20260004557A (ko) 2026-01-08
CN110198728A (zh) 2019-09-03
CA3043892A1 (en) 2018-05-24
MX2024008221A (es) 2024-07-19
WO2018094278A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
MX2019005751A (es) Tratamiento de enfermedades e infecciones de las vias respiratorias con composiciones de acido ascorbico.
BR112020008664A8 (pt) Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
CY1121701T1 (el) Οργανικες ενωσεις μονοβακταμης για την αντιμετωπιση βακτηριακων λοιμωξεων
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
CL2018001145A1 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
MX377845B (es) Inhibidores de calicreína plasmática humana.
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
BR112019001980A2 (pt) inibidor de ido1 e método de preparação e aplicação do mesmo
MX2019009185A (es) Compuesto heterociclico novedoso, su metodo de preparacion y composicion farmaceutica que lo comprende.
CO6620068A2 (es) Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi)
MX392523B (es) Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar
AR077372A1 (es) Composiciones y metodos para tratar infecciones oftalmicas oticas o nasales
MX378266B (es) Inhibidores de gingipaina de lisina.
BR112017016084A2 (pt) composição e método para o tratamento da doença veno-oclusiva hepática
MX376475B (es) Derivado de polimixina y usos del mismo.
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
MX2019013291A (es) Compuestos y metodos para tratar infecciones bacterianas.
CR20180111A (es) Agentes antibacteriales que comprenden una pirazino[2,3-b] [1,4] oxazin-3-ona o un sistema de anillos relacionado
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
AR071762A1 (es) Derivados 5-hidroximetil-oxazolidin-2-ona para el tratamiento de enfermedades intestinales bacteriales
EA201992389A1 (ru) Замещенные n-арилэтил-2-аминохинолин-4-карбоксамиды и их применение
MX2017015988A (es) Derivados de manosa para tratar infecciones bacterianas.